During the past decade, Institut dHematologie de Basse Normandie conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 4 clinical trials were completed, i.e. on average, 21.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 4 clinical trials were completed. i.e. 36.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut dHematologie de Basse Normandie" #1 sponsor was "The Lymphoma Academic Research Organisation" with 9 trials, followed by "French Innovative Leukemia Organisation" with 4 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "BeiGene" with 2 trials sponsored and "University Hospital, Caen" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut dHematologie de Basse Normandie" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Acute Leukemia French Association" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "CHU de Nancy" with 1 trials as a collaborator and "Celgene" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Institut dHematologie de Basse Normandie" are "ALK-Positive Anaplastic Large Cell Lymphoma" (1 trials), "ALK-negative Anaplastic Large Cell Lymphoma" (1 trials), "AML Arising From Myelodysplastic Syndrome (MDS)" (1 trials), "Acute Lymphoblastic Leukemia" (1 trials) and "Acute Myeloblastic Leukemia" (1 trials). Many other conditions were trialed in "Institut dHematologie de Basse Normandie" in a lesser frequency.

Most popular intervention types in "Institut dHematologie de Basse Normandie" are "Drug" (21 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Azacitidine" (2 trials), "Ibrutinib" (2 trials), "Tislelizumab" (2 trials) and "Venetoclax" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institut dHematologie de Basse Normandie" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Institut dHematologie de Basse Normandie". undefined are not yet recruiting, 5 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Institut dHematologie de Basse Normandie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut dHematologie de Basse Normandie, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".